Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 8 of 23 for:    ICATIBANT

A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00912093
Recruitment Status : Completed
First Posted : June 3, 2009
Results First Posted : August 6, 2014
Last Update Posted : September 22, 2014
Sponsor:
Information provided by (Responsible Party):
Shire

Tracking Information
First Submitted Date  ICMJE June 2, 2009
First Posted Date  ICMJE June 3, 2009
Results First Submitted Date  ICMJE July 11, 2014
Results First Posted Date  ICMJE August 6, 2014
Last Update Posted Date September 22, 2014
Study Start Date  ICMJE June 2009
Actual Primary Completion Date July 2012   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: July 11, 2014)
Time to Onset of Symptom Relief for an Acute Attack, as Assessed by the Patient [ Time Frame: Up to 120 hours post-dose ]
Time to onset of symptom relief was calculated from study drug administration to onset of symptom relief, where onset of symptom relief was defined as the earliest of 3 consecutive measurements in which there was a 50% reduction from pretreatment in composite VAS score. Composite VAS score comprised 3 symptoms, including skin swelling, skin pain, and abdominal pain, for cutaneous and abdominal attacks and 5 symptoms, including skin swelling, skin pain, abdominal pain, difficulty swallowing, and voice change, for laryngeal attacks. Subjects who did not achieve symptom relief within the observation period were censored at the last observation time.
Original Primary Outcome Measures  ICMJE
 (submitted: June 2, 2009)
Time to symptom relief for an acute attack, as assessed by the patient [ Time Frame: Patients monitored for 8 hrs or until stable ]
Change History Complete list of historical versions of study NCT00912093 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: July 11, 2014)
  • Time to Onset of Primary Symptom Relief [ Time Frame: Up to 120 hours post-dose ]
    Time to primary symptom relief was calculated from the time of study drug administration to the onset of primary symptom relief, where onset of primary symptom relief was determined using the subject-assessed VAS score for a single primary symptom (determined by edema location) and defined as the earliest of 3 consecutive non-missing measurements in which a pre-specified reduction from the pretreatment value was met. Subjects who did not achieve primary symptom relief within the observation period were censored at the last observation time.
  • Time to Almost Complete Symptom Relief [ Time Frame: Up to 120 Hours post treatment ]
    Time to almost complete symptom relief was calculated from the time of study drug administration to almost complete symptom relief, where almost complete symptom relief was defined as the earliest of 3 consecutive non-missing measurements in which all VAS scores <10 mm. Subjects who did not achieve almost complete symptom relief within the observation period were censored at the last observation time.
  • Time to Subject-Assessed Initial Symptom Improvement [ Time Frame: Up to 120 hours post-dose ]
    Time to initial symptom improvement was calculated from the time of study drug administration to initial symptom improvement as determined by the subject as the time they felt symptoms were starting to improve. Subjects who did not achieve initial symptom improvement within the observation period were censored at the last observation time.
  • Time to Investigator-Assessed Initial Symptom Improvement [ Time Frame: Up to 120 hours post-dose ]
    Time to initial symptom improvement was calculated from the time of study drug administration to initial symptom improvement as determined by the investigator as the time they felt symptoms were starting to improve. Subjects who did not achieve initial symptom improvement within the observation period were censored at the last observation time.
Original Secondary Outcome Measures  ICMJE
 (submitted: June 2, 2009)
  • Change in VAS score from pretreatment [ Time Frame: 4 and 8 hours post-treatment ]
  • Evaluation of global outcome of treatment using symptom severity score (by patient and investigator) [ Time Frame: Up to 12 hours post-treatment ]
  • Assessment of global improvement(by patient and investigator) [ Time Frame: 4 and 8 hours post-treatment ]
  • Global assessment of symptoms (by investigator) [ Time Frame: 4 and 8 hours post-treatment ]
  • Time(s) to initial symptom improvement and almost complete symptom relief [ Time Frame: Up to 5 days post-treatment ]
  • Safety and tolerability [ Time Frame: Up to 14 days post-treatment ]
  • Time to reduction in symptom severity of laryngeal attacks [ Time Frame: Up to Day 5 post-treatment ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3)
Official Title  ICMJE A Phase III Randomized, Double-Blind,Placebo-Controlled, Multicenter Study of Icatibant for Subcutaneous Injection in Patients With Acute Attacks of Hereditary Angioedema (HAE)
Brief Summary This study is being conducted to evaluate the efficacy and safety of icatibant compared to placebo in patients experiencing acute attacks of hereditary angioedema (HAE).
Detailed Description

This Phase III study consisted of two parts: A controlled phase and an open label extension (OLE) phase.

The controlled phase describes the double blind part of the study and was intended to evaluate the efficacy and safety of icatibant compared with placebo for the first treated cutaneous and/or abdominal attack.

Patients with moderate to severe abdominal or cutaneous attacks were randomized to receive a single, blinded, subcutaneous injection of icatibant (30 mg) or placebo. After a protocol amendment, patients with mild to moderate laryngeal HAE attacks were also randomized to receive a single, blinded subcutaneous injection of icatibant (30 mg) or placebo in order to obtain blinded, controlled efficacy and safety data for this subset of subjects. Patients experiencing severe laryngeal attacks (post-amendment) or mild to severe laryngeal attacks (pre-amendment) were to receive open-label icatibant.

After treatment of the first attack in the controlled phase, patients were eligible to enter the OLE phase. In the OLE phase, patients who experienced angioedema attacks severe enough to warrant treatment were to be treated with s.c. icatibant as appropriate until the study was discontinued or the product was commercially available.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Hereditary Angioedema
Intervention  ICMJE
  • Drug: Icatibant
    Single subcutaneous injection of icatibant, 30 mg
    Other Name: Firazyr
  • Drug: Placebo
    Single subcutaneous injection of matching placebo
Study Arms  ICMJE
  • Placebo Comparator: Placebo
    Single subcutaneous injection of matching placebo
    Intervention: Drug: Placebo
  • Experimental: Icatibant
    Single subcutaneous injection of icatibant, 30 mg
    Intervention: Drug: Icatibant
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: April 18, 2013)
98
Original Estimated Enrollment  ICMJE
 (submitted: June 2, 2009)
88
Actual Study Completion Date  ICMJE July 2012
Actual Primary Completion Date July 2012   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

Each patient must meet the following criteria to be enrolled in this study.

  1. The patient is ≥18 years old at the time of informed consent.
  2. The patient has a documented diagnosis of HAE type I or II. The diagnosis will be confirmed either by documented decreased C4 levels and/or immunogenic or functional C1-INH deficiency results (<50% of normal levels) consistent with HAE types I and II or by medical history.
  3. The current HAE attack must be in the cutaneous, abdominal and/or laryngeal (inclusive of laryngeal and pharyngeal) areas.
  4. Cutaneous or abdominal HAE attacks must be moderate to very severe as determined by investigator global assessment at pre-treatment assessments
  5. The patient must report at least 1 VAS score ≥ 30mm
  6. The patient commences treatment within 6 hours of the attack becoming at least mild (laryngeal) or moderate (non-laryngeal) in severity, but not more than 12 hours after the onset of the attack.
  7. Women of childbearing potential must have a negative urine pregnancy test and must use appropriate methods to prevent pregnancy during their participation in the study.

Exclusion Criteria:

Patients who meet any of the following criteria will be excluded from the study.

  1. The patient has a diagnosis of angioedema other than HAE type I or II.
  2. The patient has received previous treatment with icatibant.
  3. The patient has participated in a clinical trial and has received treatment with another investigational medicinal product within the past 30 days.
  4. The patient has received treatment with any pain medication since the onset of the current angioedema attack.
  5. The patient has received replacement therapy (fresh frozen plasma [FFP], C1-INH products) less than 5 days (120 hours) from the onset of the current angioedema attack.
  6. The patient is receiving treatment with angiotensin converting enzyme (ACE) inhibitors.
  7. Evidence of coronary artery disease based on medical history or screening examination in particular unstable angina pectoris or severe coronary heart disease;
  8. The patient has a serious concomitant illness or condition that, in the opinion of the Investigator, would be a contraindication for participation in the trial.
  9. The patient is pregnant or breastfeeding.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Australia,   Canada,   Hungary,   Israel,   Romania,   Russian Federation,   South Africa,   Ukraine,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00912093
Other Study ID Numbers  ICMJE HGT-FIR-054
2009-015606-19 ( EudraCT Number )
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Shire
Study Sponsor  ICMJE Shire
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Alan Kimura, M.D., PhD Shire
PRS Account Shire
Verification Date July 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP